Review article: Gastro-oesophageal reflux disease - The health economic implications

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 1, 2005, Pages 20-31

  Mason, J ^a   Hungin, A P S ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; DIMETICONE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT;

ABSENTEEISM; BEHAVIOR MODIFICATION; BUDGET; CLINICAL TRIAL; CONSULTATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG MARKETING; DRUG THERAPY; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENERAL PRACTITIONER; HEALTH ECONOMICS; HUMAN; LIFESTYLE; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MODEL; NATIONAL HEALTH SERVICE; ON DEMAND TREATMENT; OUTCOMES RESEARCH; PATIENT ATTITUDE; PATIENT CARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SELF MEDICATION; THERAPY; UNITED KINGDOM;

EID: 23844508159     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02606.x     Document Type: Review

References (58)

1. Anonymous. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576-9.
2. Chiba N. Definitions of dyspepsia: time for a reappraisal. Eur J Surg Suppl 1998; 164: 14-23.
3. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42.
4. North of England Dyspepsia Guideline Development Group. Dyspepsia: Managing Dyspepsia in Adults in Primary Care. Centre for Health Services Research, Report No. 112. Newcastle, UK: University of Newcastle, 2004.
5. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44: S1-S16.
6. Robertson DA, Aldersley MA, Shepherd H, Lloyd RS, Smith CL. H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response? Gut 1987; 28: 946-9.
7. Breumelhof R, Smout AJPM. The symptoms sensitivity index: a valuable additional parameter in 24 hour esophageal pH recording. Am J Gastroenterol 1991; 86: 160-4.
8. Shi G, Bruley des Varannes S, Scarpignato C, LeRhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.
9. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the 'sensitive oesophagus'. Gut 1997; 40: 587-90.
10. Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-5.
11. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
12. Wiklund I, Talley NJ. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3: 341-50.
13. Department of Health. Hospital Episode Statistics 1994-95. London, UK: Department of Health, 1996.
14. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999; 72: 93-100.
15. Quine MA, Bell GD, McCloy RF, Charlton JE, Devlin HB, Hopkins A. Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods. Gut 1995; 36: 462-7.
16. Galloway JM, Gibson J, Dalrymple J. Endoscopy in primary care - a survey of current practice. Br J Gen Pract 2002; 52: 536-8.
17. Vakil N, Rydén-Bergsten T, Bergenheim K. Systematic review: Patient-centred endpoints in economic evaluations of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1469-80.
18. Department of Health. Prescription Cost Analysis: England 1998-2003. Available at: http://www.publications.doh.gov. uk/prescriptionstatistics/index. htm. Accessed 24 May 2005.
19. McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice. Fourth National Study 1991-1992. Office of Population Censuses and Surveys, Series MB5 No. 3. London, UK: HMSO, 1995.
20. Curtis L, Netten A. Unit Costs of Health and Social Care 2004. Kent, UK: University of Kent, 2004.
21. Department of Health. Reference Costs: England 1998-2003. Available at: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/ NHSReferenceCosts/fs/en. Accessed 24 May 2005.
22. Royal College of Physicians. Consultant Physicians Working for Patients. The Duties, Responsibilities and Practice of Physicians, 2nd edn. London, UK: Royal College of Physicians, 2001.
23. McIntyre A. Healthy expansion of gastroenterology posts in England and Wales. BSG News 2000; 8: 1.
24. Smith PM, Williams R. A comparison of workloads of physician- gastroenterologists and other consultant physicians. Prepared on behalf of the Clinical Services Committee, British Society of Gastroenterology. J R Coll Physicians Lond 1992; 26: 167-8.
25. Mintel International Group Limited. Gastro-intestinal Remedies. UK: Mintel International Group Limited, 2002.
26. Mintel International Group Limited. Gastro-intestinal Remedies. UK: Mintel International Group Limited, 2004.
27. Barham C, Leonard J. National Statistics Feature: Trends and Sources of Data on Sickness Absence 2002. Office for National Statistics, 2002. Available at: http://www.statistics.gov.uk. Accessed 24 May 2005.
28. Office for National Statistics. Labour Force Survey: Summary of Labour Market Structure - Aged 16+ (SA). Office for National Statistics, 2004. Available at: http://www.statistics.gov.uk. Accessed 24 May 2005.
29. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002; 50: 10-2.
30. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000; 355: 1665-9.
31. Agréus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002; 20: 347-55.
32. World Health Organisation. Purchasing Power Parities 1995-2000. Available at: http://www3.who.int/whosis/cea/prices/ppp.cfm. Accessed 24 May 2005.
33. Stalhammar NO. Assessing the cost-effectiveness of medical treatments in acid-related diseases. The Markov chain approach applied to a comparison between intermittent and maintenance treatment of reflux esophagitis. Scand J Gastroenterol Suppl 1993; 199: 8-13.
34. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997; 102: 78-88.
35. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395-407.
36. Ofman JJ, Dorn GH, Fennertyà MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 261-73.
37. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 657-65.
38. Goeree R, O'Brien B, Hunt R, Blackhouse G, Willan A, Watson J. Economic evaluation of long term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16: 679-97.
39. Pollock K, Grime J, Blenkinsopp A. Proton Pump Inhibitors: Perspectives of Patients and their GPs. Keele: Department of Medicines Management, Keele University, 1998.
40. Grime JC, Pollock K. How do younger patients view long-term treatment with proton pump inhibitors? J R Soc Promot Health 2002; 122: 43-9.
41. Grime JC, Pollock K, Blenkinsopp A. Proton pump inhibitors: perspectives of patients and their GPs. Br J Gen Pract 2001; 51: 703-11.
42. Pollock K, Grime J. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self regulation of treatment may be an under-exploited resource. Soc Sci Med 2000; 51: 1827-39.
43. Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003; 17: 1309-17.
44. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
45. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54.
46. Talley NJ, Venables TL, Green JRB, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastrooesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63.
47. Cooper AL, Baxter G. Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut 2003; 52 (Suppl. VI): A137 (TUE-G-087).
48. Bytzer P, Blum AL, de Herdt D. On-demand rabeprazole therapy provides heartburn control in long-term management of nonerosive reflux disease (NERD) (abstract). Gastroenterology 2003; 124: S1591.
49. Kaspari S, Kupcinskas L, Fischer R, Berghoefer P. On-demand therapy with pantoprazole 20 mg as effective long-term management of patients suffering from mild GERD (abstract). Gastroenterology 2003; 124: T1640.
50. Tsai H, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oeosphageal reflux patients: the COMMAND Study 2003. Eur J Gastroenterol Hepatol 2003 (in press).
51. Bour B, Chousterman M, Labayle D, et al. On-demand maintenance therapy with rabeprazole (RAB) 10 mg: an effective alternative to continuous therapy for patients with frequent gastroesophageal reflux symptom relapse (abstract). Gastroenterology 2003; 124: S1601.
52. Lacevic N, Vukobrat-Bijedic Z, Gavrankapetanovic F, Gribajcevic M, Husic-Selimovic A, Tanovic H. Efficacy of continued and 'on demand' regimens If pantoprazole 20 mg in mild gastroesophageal reflux disease (abstract). Gut 2003; 52 (Suppl. VI): A128.
53. Engels LGJB, Klinkenberg-Knol EC, Dekkers CPM, et al. Esomeprazole continuous versus on demand maintenance therapy in 1052 gastro-oesophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment (abstract). Gut 2003; 52 (Suppl. VI): A130.
54. Johnsson F, Moum B, Villen M, Grove O, Simren M, Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002; 37: 642-7.
55. Galmiche JP, Shi G, Simon B, Casset-Semanaz F, Slama A. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther 1998; 12: 909-17.
56. Bardhan KD, Müller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999; 318: 502-7.
57. Bytzer P, Blum AL. Personal view: Rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 389-98.
58. Meineche-Schmidt V, Hauschildt Juhl H, Østergaard JE, Luckow A, Hvenegaard A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004; 19: 907-15.